Enrotron Flavoured Tablets are for the treatment of bacterial single or combined infections of the respiratory, alimentary or urinary tract, the skin or wounds, caused by Enrofloxacin-sensitive gram-negative and gram-positive bacteria: E. coli, Pasteurella spp., Haemophilus spp. and staphylococci.
Enrotron Tablets are round tablets that are white to off-white in colour with a single break line for easy and accurate dosing.
Do not use in young or growing dogs (dogs aged less than 12 months (small breed) or less than 18 months (large breed)) as the product may cause epiphyseal cartilage alterations in growing puppies.
Do not use in dogs having seizure disorders, since enrofloxacin may cause CNS stimulation.
Do not use in dogs with known hypersensitivity to fluoroquinolones or to any of the excipients of the product. Do not use in case of resistance to quinolones, as there exists almost complete cross resistance to other quinolones and complete cross resistance to other fluoroquinolones.
Do not use with tetracyclines, phenicol's or macrolides because of potential antagonistic effects.
Special warnings for each target species
Special precautions for use in animals
Official and local antimicrobial policies should be taken into account when the product is used.
Skin infections are mostly secondary to an underlying disease. It is advisable to determine the underlying cause and to treat the animal accordingly.
Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.
Whenever possible, fluoroquinolones should only be used based on susceptibility testing. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential cross resistance.
As enrofloxacin is metabolized by the liver and partly eliminated via the kidneys, elimination may be delayed in dogs with liver or renal disturbances. Therefore, in cases of known liver or renal impairment, the product should be used with caution. The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to fluoroquinolones should avoid contact with the veterinary medicinal product.
Wash hands after use.
In case of contact with the eyes, wash immediately with plenty of clean water.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Adverse reactions (frequency and seriousness)
In rare cases vomiting and diarrhoea are observed.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reaction(s) during the course of one treatment
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)
Use during pregnancy, lactation or lay
Do not use during pregnancy.
Do not use during lactation.
Interaction with other medicinal products and other forms of interaction
Concurrent use of flunixin should be under careful veterinary monitoring, as the interactions between these drugs may lead to adverse events related to delayed elimination.
Elimination of theophylline may be delayed.
Antagonistic effect may occur if enrofloxacin is combined with phenicol's, macrolide antibiotics or tetracyclines.
Substances containing magnesium or aluminium, if administered at the same time, may impair the enrofloxacin resorption
Amounts to be administered and administration route
Tablet for oral use.
Dose: 5 mg enrofloxacin per kg body weight (BW) daily, corresponding to:
½ tablet for 5 kg body weight
1 tablet per 10 kg body weight.
Can be administered directly or given with food.
Treatment generally takes place over 5 - 10 consecutive days.
If there is no clinical improvement within 3 days, the sensitivity test is to be repeated and it may be necessary to switch to a different treatment.
The recommended doses should not be exceeded.
To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing.
Overdose (symptoms, emergency procedures, antidotes), if necessary
Overdosing can cause vomiting and nervous signs (muscle tremor, incoordination and convulsions) which may require treatment discontinuation.
In the absence of any known antidote, apply drug elimination methods and symptomatic treatment.
If necessary, administration of aluminium- or magnesium-containing antacids or activated carbon can be used to reduce absorption of enrofloxacin.
According to literature, signs of overdose with enrofloxacin in dogs such as inappetence and gastrointestinal disturbance were observed at approximately 10 times the recommended dose when administered for two weeks. No signs of intolerance were observed in dogs administered 5 times the recommended dose for a month.